Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity
Bettina Mittendorfer, Brandon D. Kayser, Mihoko Yoshino, Jun Yoshino, Jeramie D. Watrous, Mohit Jain, J. Christopher Eagon, Bruce W. Patterson, Samuel Klein
Bettina Mittendorfer, Brandon D. Kayser, Mihoko Yoshino, Jun Yoshino, Jeramie D. Watrous, Mohit Jain, J. Christopher Eagon, Bruce W. Patterson, Samuel Klein
View: Text | PDF
Clinical Research and Public Health Metabolism

Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity

  • Text
  • PDF
Abstract

BACKGROUND There is considerable heterogeneity in the effect of weight loss on metabolic function in people with obesity.METHODS We evaluated muscle and liver insulin sensitivity, body composition, and circulating factors associated with insulin action before and after approximately 20% weight loss in women identified as “Responders” (n = 11) or “Non-responders” (n = 11), defined as the top (>75% increase) and bottom (<5% increase) quartiles of the weight loss–induced increase in glucose disposal rate (GDR) during a hyperinsulinemic-euglycemic clamp procedure, among 43 women with obesity (BMI: 44.1 ± 7.9 kg/m2).RESULTS At baseline, GDR, which provides an index of muscle insulin sensitivity, and the hepatic insulin sensitivity index were more than 50% lower in Responders than Non-responders, but both increased much more after weight loss in Responders than Non-responders, which eliminated the differences between groups. Weight loss also caused greater decreases in intrahepatic triglyceride content and plasma adiponectin and PAI-1 concentrations in Responders than Non-responders and greater insulin-mediated suppression of plasma free fatty acids, branched-chain amino acids, and C3/C5 acylcarnitines in Non-responders than Responders, so that differences between groups at baseline were no longer present after weight loss. The effect of weight loss on total body fat mass, intra-abdominal adipose tissue volume, adipocyte size, and circulating inflammatory markers were not different between groups.CONCLUSION The results from our study demonstrate that the heterogeneity in the effects of marked weight loss on muscle and hepatic insulin sensitivity in people with obesity is determined by baseline insulin action, and reaches a ceiling when “normal” insulin action is achieved.TRIAL REGISTRATION NCT00981500, NCT01299519, NCT02207777.FUNDING NIH grants P30 DK056341, P30 DK020579, P30 DK052574, UL1 TR002345, and T32 HL13035, the American Diabetes Association (1-18-ICTS-119), the Longer Life Foundation (2019-011), and the Atkins Philanthropic Trust.

Authors

Bettina Mittendorfer, Brandon D. Kayser, Mihoko Yoshino, Jun Yoshino, Jeramie D. Watrous, Mohit Jain, J. Christopher Eagon, Bruce W. Patterson, Samuel Klein

×

Figure 4

Plasma metabolite profile.

Options: View larger image (or click on image) Download as PowerPoint
Plasma metabolite profile.
(A) Principal component analysis of the 127 m...
(A) Principal component analysis of the 127 monitored plasma metabolites, shown with 68% confidence ellipses, in Responders (n = 11) and Non-responders (n = 11). (B) Baseline between group differences (R/NR Before) and weight-loss induced within group differences (After/Before) in the basal abundances of 12 metabolites for which repeated measures analysis of variance with group and time as factors revealed both a group × time interaction (P < 0.10) and a significant change (5% false discovery rate) with weight loss in Responders (n = 11) or both Responders and Non-responders (n = 11). (C) Baseline between group differences (R/NR Before) and weight-loss induced within group differences (After/Before) in the abundances of 36 metabolites during insulin infusion for which repeated measures ANOVA with group and time as factors revealed both a group × time interaction (P < 0.10) and a significant change (5% false discovery rate) with weight loss in Responders (n = 11) only or both Responders and Non-responders (n = 11). (D) Abundances of a priori–selected metabolites during basal conditions and during insulin infusion before and after weight loss in Responders (n = 11) and Non-responders (n = 11). Data are normalized to the Responders before weight loss value as reference. Data are mean ± SEM. Repeated measures ANOVA was used to evaluate the effects of group and time on the outcome values in panels B–D. *P < 0.05 versus corresponding value before weight loss. fP < 0.05 versus corresponding value in Responders. There was a significant (P < 0.05) effect of insulin (vs. basal) for free fatty acids, branched-chain amino acids, and acylcarnitines. BCAA, branched-chain amino acids; FFA, free fatty acids (sum of palmitate, oleate, and linoleate); NR, Non-responders; PC, principal component; R, Responders.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts